Literature DB >> 2376572

Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver.

T Deguchi1, M Mashimo, T Suzuki.   

Abstract

Southern blot analysis was performed with genomic DNAs from 86 human subjects using the 32P-labeled cDNA for polymorphic arylamine N-acetyltransferase (EC 2.3.1.5) in human liver recently cloned in our laboratory. Three types of N-acetyltransferase gene were identified. Gene 1 contains a 5.5-kilobase (kb) KpnI fragment with a BamHI site; gene 2 contains a 5.5-kb KpnI fragment without a BamHI site; and gene 3 contains a 5.0-kb KpnI fragment with a BamHI site. The combination of these three genes generated five genotypes. Acetylator phenotypes were determined in 29 healthy volunteers by isoniazid loading tests, and they were classified as rapid (10 subjects), intermediate (16 subjects), or slow (3 subjects) acetylators. Rapid acetylators were homozygotes of gene 1. Intermediate acetylators were heterozygotes of either genes 1 and 2 or genes 1 and 3. There were two exceptional cases who were classified as intermediate acetylators but were homozygotes of gene 1. Slow acetylators were either heterozygote of genes 2 and 3 or homozygotes of gene 3. These results indicate that gene 1 corresponds to high N-acetyltransferase activity, while gene 2 and gene 3 give rise to low N-acetyltransferase activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2376572

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 2.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  Molecular genotyping of N-acetylation polymorphism to predict phenotype.

Authors:  M Mashimo; T Suzuki; M Abe; T Deguchi
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

4.  Kinetics of acetyl coenzyme A: arylamine N-acetyltransferase from human cumulus cells.

Authors:  C C Chang; Y Y Hsieh; J G Chung; H D Tsai; C H Tsai
Journal:  J Assist Reprod Genet       Date:  2001-09       Impact factor: 3.412

Review 5.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

6.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

7.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

8.  Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.

Authors:  Mark A Doll; Yu Zang; Timothy Moeller; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

9.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

10.  Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans.

Authors:  Yan Wei Zhang; Sang-Yong Eom; Yong-Dae Kim; Young-Jin Song; Hyo-Yung Yun; Joo-Seung Park; Sei-Jin Youn; Byung Sik Kim; Heon Kim; David W Hein
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.